Jane Street Group LLC Has $233,000 Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Jane Street Group LLC cut its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 53.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,281 shares of the company’s stock after selling 15,425 shares during the quarter. Jane Street Group LLC’s holdings in Pulse Biosciences were worth $233,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Quest Partners LLC acquired a new position in shares of Pulse Biosciences during the second quarter worth approximately $91,000. Rhumbline Advisers lifted its holdings in shares of Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after buying an additional 1,608 shares during the last quarter. Creative Planning lifted its holdings in shares of Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after buying an additional 11,667 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after buying an additional 9,639 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pulse Biosciences during the third quarter worth approximately $588,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Robert W. Duggan purchased 56,054 shares of the stock in a transaction on Wednesday, December 11th. The shares were purchased at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the transaction, the director now directly owns 42,228,057 shares of the company’s stock, valued at approximately $732,656,788.95. The trade was a 0.13 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 71.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Stock Performance

PLSE opened at $18.47 on Friday. Pulse Biosciences, Inc. has a 1 year low of $6.59 and a 1 year high of $22.69. The stock’s 50 day simple moving average is $18.24 and its 200-day simple moving average is $17.21.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter last year, the company posted ($0.19) earnings per share.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.